NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript
Seeking Alpha7/29/2026Neutral
NEO
NeoGenomics IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$1.74B
P/E Ratio
—
EPS
$-0.79
Beta
1.74
52W High
$15.57
52W Low
$4.72
50-Day MA
$12.08
200-Day MA
$10.72
Dividend Yield
—
Profit Margin
-13.30%
Forward P/E
222.22
PEG Ratio
2.09
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Fundamentals
| Revenue (TTM) | $745.97M |
| Gross Profit (TTM) | $321.51M |
| EBITDA | $4.27M |
| Operating Margin | -9.34% |
| Return on Equity | -11.60% |
| Return on Assets | -2.64% |
| Revenue/Share (TTM) | $5.80 |
| Book Value | $6.39 |
| Price-to-Book | 2.07 |
| Price-to-Sales (TTM) | 2.34 |
| EV/Revenue | 2.647 |
| EV/EBITDA | -27.92 |
| Quarterly Earnings Growth (YoY) | 130.60% |
| Quarterly Revenue Growth (YoY) | 11.10% |
| Shares Outstanding | $130.21M |
| Float | $118.27M |
| % Insiders | 2.05% |
| % Institutions | 108.47% |
Historical Volatility
HV 10-Day
44.12%
HV 20-Day
42.90%
HV 30-Day
59.22%
HV 60-Day
56.82%
HV Rank
68.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($16.78 target)
2
Strong Buy6
Buy4
HoldLatest News
NeoGenomics Reports Second Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
Business Wire7/28/2026Neutral
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.
Business Wire7/20/2026Neutral
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
Business Wire7/9/2026Neutral
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
Business Wire7/7/2026Neutral
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
Business Wire6/25/2026Neutral
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research6/19/2026Positive
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha6/17/2026Neutral
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
Business Wire6/17/2026Neutral
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+
GlobeNewsWire5/20/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NEO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026